BRISBANE, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value testing solutions for transplant recipients, announces it will once again be very active at the International Society of Heart and Lung Transplantation Meeting from April 5-8, 2017 in San Diego.
Six clinical abstracts featuring AlloMap or AlloSure will be presented by the study investigators:
- Correlation of Individual Gene Expression Variability with the Variability of Combined Gene Expression Scores
E. C. DePasquale
6:15 PM Wednesday, April 5
- Correlation of Allomap® Scores in Pediatric Heart Transplant Recipients: Are we ready to apply this to our patients?
D. Gupta
6:15 PM Wednesday, April 5
- Donor-Derived Cell-Free DNA Associates with Rejection in Lung Transplantation Using Clinical-Grade Targeted Next-Generation Sequencing
S. Agbor-Enoh
11:50 AM Thursday, April 6
- Analysis of Donor-Derived Cell-Free DNA with 3-Year Outcomes in Heart Transplant Recipients
M. Crespo-Leiro
3:00 PM Thursday, April 6
- Analysis of Individual Gene Expression Levels Indicates the Impact of Physiological Functions On Gene Expression Profiling Scores
S. A. Hall
5:45 PM Friday, April 7
- Reduced PF4 and C60rf25 gene copies prior to LVAD implantation in patients with thromboembolic events
H. Kim
7:10 PM Friday, April 7
“The ISHLT Congress continues to be an ideal venue for CareDx to showcase its strong dedication and innovation to the heart transplant community,” said Todd Whitson, Chief Commercial Officer at CareDx, Inc. “We continue to look for better ways to partner with transplant centers in order to improve patient care and maximize long-term outcomes.”
Additional information on CareDx presentations and data can be found at the CareDx booth at ISHLT (Booth #121).
About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients. CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation.
CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts including, but not limited to the development, commercialization, utility, performance and adoption of AlloSure. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risk associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016 and the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 filed by us with the SEC on November 14, 2016. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.